Jeff Johnson
Stock Analyst at Baird
(4.64)
# 183
Out of 5,102 analysts
150
Total ratings
58.25%
Success rate
28.39%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $85 → $98 | $82.11 | +19.35% | 19 | Dec 5, 2025 | |
| ALC Alcon | Maintains: Outperform | $95 → $98 | $78.76 | +24.43% | 11 | Nov 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $68.94 | +30.55% | 15 | Sep 26, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $29.31 | -42.00% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $76.24 | -5.56% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $22.14 | +3.88% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $92.45 | +24.39% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $20.97 | +14.45% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $352.97 | +14.74% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $163.87 | +68.43% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $294.17 | -19.09% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $27.82 | +151.62% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.45 | +322.15% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $11.60 | +477.84% | 6 | Feb 18, 2022 |
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $98
Current: $82.11
Upside: +19.35%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95 → $98
Current: $78.76
Upside: +24.43%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $68.94
Upside: +30.55%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $29.31
Upside: -42.00%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $76.24
Upside: -5.56%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $22.14
Upside: +3.88%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $92.45
Upside: +24.39%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $20.97
Upside: +14.45%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $352.97
Upside: +14.74%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $163.87
Upside: +68.43%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $294.17
Upside: -19.09%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $27.82
Upside: +151.62%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.45
Upside: +322.15%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $11.60
Upside: +477.84%